Immediate Versus Deferred Hormonal Treatment For Patients With Prostate Cancer Who Are Not Suitable For Curative Local Treatment: Results Of The Randomized Trial Sakk 08/88

Urs E Studer,Dieter Hauri, Silvia Hanselmann, Dominique Chollet,Hans-Jürg Leisinger,Thomas Gasser, Edgar Senn, Felix B Trinkler, Reto M Tscholl,George N Thalmann,Daniel R Dietrich

JOURNAL OF CLINICAL ONCOLOGY(2004)

引用 89|浏览4
暂无评分
摘要
Purpose To determine if immediate hormonal therapy is advantageous compared with deferred treatment in newly diagnosed asymptomatic prostate cancer patients who, for any reason, were not candidates for curative local treatment.Patients and Methods Between February 1988 and February 1992, 197 patients with a median age of 76 years (range, 56 to 86 years) were randomly assigned to receive either immediate or deferred orchiectomy on symptomatic progression. The two groups did not differ significantly in clinical or laboratory parameters; 67% had T3-4 tumors and 20% had lymph node metastases. Patient accrual was stopped prematurely because of a similar competing trial. Therefore, observation time was prolonged to achieve the desired number of events and statistical power.Results Deferred orchiectomy was necessary in 58% of the patients. Median time to disease progression was 2.8 years less than for patients with immediate orchiectomy. However, overall pain-free time from random assignment to symptomatic progression after immediate or deferred orchiectomy, and performance status, were identical in both groups. Cancerspecific survival tended to be longer in the immediate group (P = .09) but there was no difference in overall survival between the two groups (P = .96). The median hemoglobin value decreased significantly after immediate orchiectomy (P < .001).Conclusion For elderly, asymptomatic patients not undergoing curative local treatment, we were unable to show any major advantage of immediate compared with deferred hormonal treatment regarding quality of life or overall survival in our limited number of patients. Disabling complications were prevented in the deferred-treatment arm by careful follow-up; 42% of these patients never required any tumor-specific treatment. (C) 2004 by American Society of Clinical Oncology.
更多
查看译文
关键词
randomized trial
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要